Indaptus rises on positive pre-clinical efficacy data for anti-tumor platform
19/04/2023 16:29
** Shares of drug Developer Indaptus Therapeutics Inc
INDP.O rise 5.3% to $2.6
** Co reports positive preclinical efficacy data for its
bacteria-based immunotherapy platform technology, Decoy
** Says Decoy 10 demonstrated 90% reduction of bacterial
toxins activity and use of 100% killed, bacteria that do not
cause disease, harm or death
** Decoy 10 data conferred the ability to activate both
innate and adaptive immune pathways in tumors after a
single-safe intravenous dose in combination with checkpoint
inhibitor anticancer drugs, co says
** Adds in vivo anti-tumor activity was seen with different
cancers, including non-Hodgkin's lymphomas in pre-clinical
models
** Including session moves, co's stock up 77.9% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))